CONTENTS

UNIT ONE

Basic Concepts and Principles in Pharmacology, 1

Introduction to Respiratory Care Pharmacology, 2 Douglas S. Gardenhire

Pharmacology and the Study of Drugs, 3 Naming Drugs, 3 Sources of Drug Information, 5 Sources of Drugs, 5 Process for Drug Approval in the United

States, 5 The Prescription, 7

Respiratory Care Pharmacology: An Overview, 9

2 Principles of Drug Action, 11

Douglas S. Gardenhire

Pharmacokinetic Phase, 14 Pharmacodynamic Phase, 23 Pharmacogenetics, 29

3 Administration of Aerosolized Agents, 31

Douglas S. Gardenhire

Physical Principles of Inhaled Aerosol Drugs, 32
Aerosol Generators for Drug Delivery, 36
Selecting an Aerosol Device, 56
Clinical Application of Aerosol Delivery
Devices, 58

4 Calculating Drug Doses, 66

Douglas S. Gardenhire

Systems of Measure, 66
Calculating Doses From Prepared-Strength
Solutions, 68
Calculating Doses From Percentage-Strength

5 Central and Peripheral Nervous Systems, 77

Douglas S. Gardenhire

Solutions, 70

Nervous System, 78
Autonomic Branches, 78
Parasympathetic Branch, 81
Cholinergic Agents, 83
Anticholinergic Agents, 84
Sympathetic Branch, 85
Sympathomimetic (Adrenergic) and Sympatholytic (Antiadrenergic) Agents, 89

Neural Control of Lung Function, 89

UNIT TWO

Drugs Used to Treat the Respiratory System, 96

6 Adrenergic (Sympathomimetic) Bronchodilators, 97

Douglas S. Gardenhire

Clinical Indications for Adrenergic
Bronchodilators, 98
Specific Adrenergic Agents and Formulations, 98
Mechanism of Action, 108
Routes of Administration, 111
Adverse Side Effects, 113
Compatibility of Other Agents With
Bronchodilators, 117
β-Agonist Controversy, 117
Respiratory Care Assessment of β-Agonist

7 Anticholinergic (Parasympatholytic) Bronchodilators, 122

Douglas S. Gardenhire

Therapy, 118

Clinical Indications for Use, 123
Specific Anticholinergic (Parasympatholytic)
Agents, 123
Clinical Pharmacology, 125
Mode of Action, 128
Adverse Effects, 131
Clinical Application, 132
Respiratory Care Assessment of Anticholinergic
Bronchodilator Therapy, 134

8 Xanthines, 138

Douglas S. Gardenhire

Clinical Indications for the Use of Xanthines, 139 Specific Xanthine Agents, 139 General Pharmacologic Properties, 140 Titrating Theophylline Doses, 142 Respiratory Care Assessment of Xanthines, 146

9 Mucus-Controlling Drug Therapy, 148

Bruce K. Rubin, Markus Henke

Drug Control of Mucus: A Perspective, 149 Physiology of the Mucociliary System, 150 Nature of Mucus Secretion, 153 Physical Properties of Mucus, 156 Mucoactive Agents, 157 Mucolytics and Expectorants, 158 Mucokinetic Agents, 161 Mucoregulatory Medications, 161 Other Mucoactive Agents, 162 Gene Therapy, 163
Using Mucoactive Therapy With Physiotherapy and
Airway Clearance Devices, 163
Future Mucus-Controlling Agents, 165
Respiratory Care Assessment of Mucoactive Drug
Therapy, 165

10 Surfactant Agents, 172

Douglas S. Gardenhire

Physical Principles, 173
Clinical Indications for Exogenous Surfactants, 173
Identification of Surfactant Preparations, 174
Specific Exogenous Surfactant Preparations, 177
Mode of Action, 179
Clinical Outcome, 180
Hazards and Complications of Surfactant
Therapy, 180
Future Directions in Surfactant Therapy, 180
Respiratory Care Assessment of Surfactant
Therapy, 181

11 Corticosteroids in Respiratory Care, 183

Douglas S. Gardenhire

Clinical Indications for Use of Inhaled
Corticosteroids, 184
Identification of Aerosolized Corticosteroids, 184
Physiology of Corticosteroids, 184
Nature of Inflammatory Response, 188
Aerosolized Corticosteroids, 190
Pharmacology of Corticosteroids, 193
Hazards and Side Effects of Steroids, 195
Clinical Application of Aerosol Steroids, 197
Respiratory Care Assessment of Inhaled
Corticosteroid Therapy, 199

12 Nonsteroidal Antiasthma Agents, 202

Douglas S. Gardenhire

Clinical Indications for Nonsteroidal Antiasthma Agents, 203 Identification of Nonsteroidal Antiasthma Agents, 203 Mechanisms of Inflammation in Asthma, 203 Cromolyn-Like (Mast Cell–Stabilizing) Agents, 206 Antileukotriene Agents, 209 Respiratory Care Assessment of Nonsteroidal

13 Aerosolized Antiinfective Agents, 219

Antiinfective Agents, 233

Antiasthma Agents, 216

Douglas S. Gardenhire

Clinical Indications for Aerosolized Antiinfective Agents, 220 Identification of Aerosolized Antiinfective Agents, 220 Respiratory Care Assessment of Aerosolized

14 Antimicrobial Agents, 238

Christopher A. Schriever, Susan L. Pendland

Principles of Antimicrobial Therapy, 239
Antibiotics, 244
Antimycobacterials, 255
Antifungals, 257
Antiviral Agents, 260
Respiratory Care Assessment of Antibiotic
Therapy, 262

15 Cold and Cough Agents, 265

Douglas S. Gardenhire

Sympathomimetic (Adrenergic) Decongestants, 266
Antihistamine Agents, 267
Expectorants, 269
Cough Suppressants (Antitussives), 271
Cold Compounds, 271
Respiratory Care Assessment of Cold and Cough
Agents, 272

16 Selected Agents of Pulmonary Value, 274

Douglas S. Gardenhire, Lynda T. Goodfellow

α₁-Proteinase Inhibitor (Human), 275
 Respiratory Care Assessment of Therapy of
 α₁-Proteinase Inhibitor (Human), 276
 Smoking Cessation Drug Therapy, 277
 Respiratory Care Assessment of Smoking Cessation Drug Therapy, 280
 Nitric Oxide, 280
 Respiratory Care Assessment of Nitric Oxide, 283
 Synthetic Analogs of Prostacyclin, 283
 Respiratory Care Assessment of Synthetic Analogs

of Prostacyclin, 284
Insulin Human (rDNA Origin), 284
Respiratory Care Assessment of Inhaled
Insulin, 284

17 Neonatal and Pediatric Aerosolized Drug Therapy, 287

Diana Marcela Serrato, Ruben D. Restrepo

Off-Label Use of Drugs in Neonatal and Pediatric Patients, 288

Factors Affecting Neonatal and Pediatric Aerosol Drug Delivery, 289

Nebulized Drug Distribution, 292

Clinical Response to Aerosolized Drugs in Neonata and Pediatric Patients, 294

Selection of Delivery Devices, 294

Use of Selective Agents in Neonatal and Pediatric Patients, 296

Compliance and Cooperation During Aerosol Therapy, 297

Aerosol Administration in Intubated Neonatal and Pediatric Patients, 299 Summary, 299

Critical Care, Cardiovascular, and Polysomnography Agents, 304

Skeletal Muscle Relaxants (Neuromuscular Blocking Agents), 305

Douglas S. Gardenhire

The siology of the Neuromuscular Junction, 306

Nondepolarizing Agents, 308

Depolarizing Agents, 310

Neuromuscular Blocking Agents and Mechanical

Ventilation, 312

Ventilation of Neuromuscular Blockade, 315

Monitoring of Neuromuscular Blockade, 315 Future of Neuromuscular Blocking Agents and Reversal, 316

Diuretic Agents, 318

Paben D. Restrepo

Diuretic Groups, 320
Diuretic Combinations, 325
Drug Interactions, 325
Adverse Effects, 325
Special Situations, 326

Drugs Affecting the Central Nervous System, 330
Douglas S. Gardenhire

Neurotransmitters, 332
Psychiatric Medications, 333
Ethyl Alcohol, 336
Pain Treatment, 337
Chronic Pain Syndromes, 341
Anesthesia, 342
Central Nervous System and Respiratory
Stimulants, 344

Vasopressors, Inotropes, and Antiarrhythmic Agents, 347

Henry Cohen

Overview of Cardiovascular System, 348
Agents Used in the Management of Shock, 352
Electrophysiology of Myocardium, 354
Pharmacology of Antiarrhythmics, 356
Management and Pharmacotherapy of Advanced
Cardiac Life Support, 365
Alternative Routes of Medication
Administration, 368

22 Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics, 370 Henry Cohen

Hypertension, 371 Hypertension Pharmacotherapy, 374 Angina, 385 Antithrombotic Agents, 388

23 Sleep and Sleep Pharmacology, 408
Ahmed S. BaHammam, David N. Neubauer,
Seithikurippu R. Pandi-Perumal

History of Treatment of Sleep Disorders, 409 Progression of Sleep, 410 Neurophysiologic Mechanisms, 414 Sleep Disorders: Causes and Treatments, 419

Appendixes

- A Answers to Self-Assessment Questions and Clinical Scenarios, 427
- **B** Units and Systems of Measurement, 450
- Acceptable Mixtures of Most Commonly Prescribed Respiratory Care Drugs, 454

Glossary of Selected Terms, 455

Drug Index, 463

Index, 479

Abbreviations, Inside back cover